{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:59:41Z","timestamp":1792223981112,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011105","name":"National University Cancer Institute, Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-020-0276-7","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T18:03:41Z","timestamp":1580148221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Sanjay","family":"de Mel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masturah B. M.","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Tsu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Mei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H. L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Lin","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Ching","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Quan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burton K. H.","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurike","family":"Laurensia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7518-4081","authenticated-orcid":false,"given":"DaChuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Lu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl Ming Zhe","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Kam Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6402-4288","authenticated-orcid":false,"given":"Choon Kiat","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Thye","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siok Bian","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Yong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Yin","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lip Kun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-6137","authenticated-orcid":false,"given":"Anand D.","family":"Jeyasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"key":"276_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00451-5","volume":"8","author":"S Chia","year":"2017","unstructured":"Chia, S. et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 8, 435 (2017).","journal-title":"Nat Commun."},{"key":"276_CR2","doi-asserted-by":"publisher","unstructured":"Rashid, M. et al. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan0941 (2018).","DOI":"10.1126\/scitranslmed.aan0941"},{"key":"276_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-5-88","volume":"5","author":"I Al-Shyoukh","year":"2011","unstructured":"Al-Shyoukh, I. et al. Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst. Biol. 5, 88 (2011).","journal-title":"BMC Syst. Biol"},{"key":"276_CR4","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","volume":"102","author":"K Belhadj","year":"2003","unstructured":"Belhadj, K. et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102, 4261\u20134269 (2003).","journal-title":"Blood"},{"key":"276_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.critrevonc.2011.10.001","volume":"83","author":"AJ Ferreri","year":"2012","unstructured":"Ferreri, A. J., Govi, S. & Pileri, S. A. Hepatosplenic gamma-delta T-cell lymphoma. Crit. Rev. Oncol. Hematol. 83, 283\u2013292 (2012).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"276_CR6","first-page":"269","volume":"24","author":"H Xu","year":"2014","unstructured":"Xu, H., Jaynes, J. & Ding, X. Combining two-level and three-level orthogonal arrays for factor screening and response surface exploration. Stat. Sinica 24, 269\u2013289 (2014).","journal-title":"Stat. Sinica"},{"key":"276_CR7","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1200\/JCO.2001.19.9.2390","volume":"19","author":"NL Kobrinsky","year":"2001","unstructured":"Kobrinsky, N. L. et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children\u2019s Cancer Group Study CCG-5912. J. Clin. Oncol. 19, 2390\u20132396 (2001).","journal-title":"J. Clin. Oncol."},{"key":"276_CR8","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","volume":"2","author":"D Tan","year":"2015","unstructured":"Tan, D. et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2, e326\u2013e333 (2015).","journal-title":"Lancet Haematol."},{"key":"276_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","volume":"82","author":"U Heider","year":"2009","unstructured":"Heider, U. et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur. J. Haematol. 82, 440\u2013449 (2009).","journal-title":"Eur. J. Haematol."},{"key":"276_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/leu.2009.41","volume":"23","author":"QL Zhang","year":"2009","unstructured":"Zhang, Q. L. et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis. Leukemia 23, 1507\u20131514 (2009).","journal-title":"Leukemia"},{"key":"276_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/ac402546b","volume":"86","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. High-throughput screening (HTS) of anticancer drug efficacy on a micropillar\/microwell chip platform. Anal. Chem. 86, 535\u2013542 (2014).","journal-title":"Anal. Chem."},{"key":"276_CR12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41588-018-0209-6","volume":"50","author":"JK Lee","year":"2018","unstructured":"Lee, J. K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat. Genet. 50, 1399\u20131411 (2018).","journal-title":"Nat. Genet."},{"key":"276_CR13","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26\u2013e37 (2017).","journal-title":"Blood"},{"key":"276_CR14","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ng.3362","volume":"47","author":"U Fischer","year":"2015","unstructured":"Fischer, U. et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat. Genet. 47, 1020\u20131029 (2015).","journal-title":"Nat. Genet."},{"key":"276_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/2211068215579612","volume":"20","author":"MB Mohd Abdul Rashid","year":"2015","unstructured":"Mohd Abdul Rashid, M. B. et al. Identification and optimization of combinatorial glucose metabolism inhibitors in hepatocellular carcinomas. J. Lab. Autom. 20, 423\u2013437 (2015).","journal-title":"J. Lab. Autom."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0276-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:24:33Z","timestamp":1670250273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0276-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0276-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"5 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.J.: honoraria from AstraZeneca, Janssen, and MSD, travel funding from Perkin Elmer, and research funding from Janssen. E.C.; shareholder in KYAN Therapeutics. The other co-authors declare no relevant conflict of interest for this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"9"}}